These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18303603)

  • 61. The Authors Respond.
    Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
    [No Abstract]   [Full Text] [Related]  

  • 62. Welcome clinical leadership at NICE.
    Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
    [No Abstract]   [Full Text] [Related]  

  • 63. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
    Geynisman DM; Hu JC; Liu L; Tina Shih YC
    Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
    Chowdhury S; Harper PG; Choueiri TK
    Nat Clin Pract Oncol; 2008 Dec; 5(12):698-9. PubMed ID: 18852722
    [No Abstract]   [Full Text] [Related]  

  • 65. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
    Bukowski RM
    Cancer; 2009 May; 115(10 Suppl):2273-81. PubMed ID: 19402065
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ["... and now about the costs!"].
    Rohde D
    Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
    [No Abstract]   [Full Text] [Related]  

  • 69. The role of socioeconomic status in renal cell carcinoma.
    Hellenthal NJ; Bermejo CE
    Urol Oncol; 2012; 30(1):89-94. PubMed ID: 21908209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Angiogenesis inhibition in non-clear cell renal cancer.
    Stadler W
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
    [No Abstract]   [Full Text] [Related]  

  • 71. New therapies after failure of angiogenesis inhibitors.
    Escudier B
    Clin Adv Hematol Oncol; 2009 Aug; 7(8):512-4. PubMed ID: 19927977
    [No Abstract]   [Full Text] [Related]  

  • 72. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
    Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
    Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.